Here, we exhibited that anti-CD70 monotherapy and anti-CD70+ anti-PD-1 combination therapy overcame Treg-mediated immunosuppression and elevated the effector function of CD8+ T cells in NPC, providing sufficient experimental evidence of how anti-CD70 treatment exerted its tumor-killing effect in a Treg-enriched TME. The gene discussed is CD8A; the disease is neoplasm.